Vyant Bio Inc
VYNT
Get informed when a big investor buys or sells
+ FollowMarket Cap$0
Close$
Share Statistics
| Market cap | $0.00 |
|---|---|
| Enterprise Value | $-7,773,000.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.87 |
| Beta | 0.56 |
| Outstanding Shares | 5,904,000 |
Return
| Return on Equity | -289.71% |
|---|---|
| Return on Assets | -188.80% |
| Return on Invested Capital | -137.89% |
Valuation & Multiples
| P/E Ratio | -0.05 |
|---|---|
| PEG | 0.09 |
| Price to Sales | - |
| Price to Book Ratio | 0.19 |
| Enterprise Value to Revenue | -11.67 |
| Enterprise Value to EBIT | 0.49 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.29 |
| Debt to Equity | 0.23 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Vyant Bio Inc
40 employees
CEO: John Roberts Vyant Bio operates two wholly-owned subsidiaries, StemoniX and vivoPharm. The Company will immediately begin to execute on the integration of these two leading businesses, to converge human-powered scientific and technology-based systems...